Showing 683 results
-
Media Release /
-
Media Release /AMG 334 (erenumab) is an investigational therapy with a novel mechanism of action for migraine prevention for patients with high unmet needMigraine is associated with pain, disability and nearly $25…
-
Media Release /
-
Media Release /- 5 year data from long-term Phase III extension study demonstrate sustained efficacy and safety of Cosentyx in patients with moderate-to-severe plaque psoriasis(1)- Data planned to be presented at a…
-
Media Release /
-
Media Release /- 83% of patients achieved complete remission (CR) or CR with incomplete blood count recovery within 3 months of treatment with CTL019; consistent with interim ELIANA data- Data evaluating 63…
-
Media Release /
-
Media Release /-- At interim analysis, three-month overall response rate (ORR) was 45%, with 37% complete response (CR); all patients in CR at three months remained in CR at data cutoff-- Best ORR was 59%, with 43…
-
Media Release /
-
Media Release /Physicians now have the option of prescribing Kisqali and Femara together in one convenient co-pack Co-Pack allows patients ability to obtain Kisqali and Femara with a single co-pay Approval comes…
